Incretin Atlas › Trials › SOUL
SOUL
Semaglutide · T2D + CVD/CKD
Design
- Molecule(s)
- Semaglutide
- Population
- T2D + CVD/CKD
- Official title
- A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Registry status
- completed · 2019-06 → 2024-08
- Participants
- 9651
- Registry
- NCT03914326
Cardiovascular and kidney outcomes
SOUL oral semaglutide 14 mg vs placebo · T2D + CVD/CKD · n = 9650 · 2025 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary Three-point MACE: CV death, nonfatal MI, or nonfatal stroke (time to first event) | 0.86 | 0.77–0.96 | 579 vs 668 | verified |
| Cardiovascular death Death from cardiovascular causes | 0.93 | 0.80–1.09 | 301 vs 320 | verified |
| All-cause death Death from any cause | 0.91 | 0.80–1.02 | 528 vs 577 | verified |
| Myocardial infarction Fatal or nonfatal myocardial infarction | 0.73 | 0.61–0.88 | 200 vs 268 | verified |
| Stroke Fatal or nonfatal stroke | 0.95 | 0.76–1.17 | 164 vs 171 | verified |
| Hospitalisation for heart failure Heart failure (hospitalization for heart failure; supportive secondary outcome, labelled 'Heart failure' in Table 2) | 0.86 | 0.69–1.08 | 146 vs 167 | verified |
| CV death or worsening HF Heart failure events: three-point composite of CV death, urgent visit for heart failure, or hospitalization for heart failure | 0.90 | 0.79–1.03 | 405 vs 443 | verified |
| Kidney composite Major kidney disease events (first confirmatory secondary): five-point composite of CV death, kidney-related death, persistent eGFR decline of >=50%, persistent | 0.91 | 0.80–1.05 | 403 vs 435 | verified |
| Expanded MACE (MACE + revasc. + UA) MACE five-point composite: death from CV causes, nonfatal MI, nonfatal stroke, coronary revascularization, or hospitalization for unstable angina | 0.84 | 0.76–0.93 | 670 vs 777 | verified |
| Major adverse limb events Major adverse limb events, two-point composite: hospitalization for acute limb ischemia or hospitalization for chronic limb ischemia (confirmatory secondary) | 0.71 | 0.52–0.96 | 71 vs 99 | verified |
| Coronary revascularisation Coronary revascularization | 0.75 | 0.62–0.90 | 200 vs 263 | verified |
| Hospitalisation for unstable angina Hospitalization for unstable angina pectoris | 0.92 | 0.67–1.26 | 74 vs 80 | verified |
Verbatim quotes (12)
- 3-point MACE · Results, Primary and Confirmatory Secondary Outcomes; Table
579 of the 4825 participants (12.0%...) in the oral semaglutide group, as compared with 668 of the 4825 participants (13.8%...) in the placebo group (hazard ratio, 0.86; 95% CI, 0.77 to 0.96
- Cardiovascular death · Results, paragraph 2; Table 2; Figure 1B
301 participants (6.2%) in the oral semaglutide group and 320 participants (6.6%) in the placebo group died from cardiovascular causes (hazard ratio, 0.93; 95% CI, 0.80 to 1.09)
- All-cause death · Table 2; Results, Supportive Secondary Outcomes
Death from any cause 528 (10.9) 2.8 577 (12.0) 3.0 0.91 (0.80–1.02)
- Myocardial infarction · Table 2; Results, Supportive Secondary Outcomes
Fatal or nonfatal myocardial infarction 200 (4.1) 1.1 268 (5.6) 1.4 0.73 (0.61–0.88)
- Stroke · Table 2; Results, Supportive Secondary Outcomes
Fatal or nonfatal stroke 164 (3.4) 0.9 171 (3.5) 0.9 0.95 (0.76–1.17)
- Hospitalisation for heart failure · Table 2
Heart failure 146 (3.0) 0.8 167 (3.5) 0.9 0.86 (0.69–1.08)
- CV death or worsening HF · Table 2; Results, Supportive Secondary Outcomes
Heart failure events, three-point composite 405 (8.4) 2.1 443 (9.2) 2.4 0.90 (0.79–1.03)
- Kidney composite · Results, paragraph 4; Table 2; Figure 1E
an event occurred in 403 participants (8.4%...) in the oral semaglutide group, as compared with 435 participants (9.0%...) in the placebo group (hazard ratio, 0.91; 95% CI, 0.80 to 1.05; P = 0.19)
- Expanded MACE (MACE + revasc. + UA) · Table 2, supportive secondary outcomes
Major adverse cardiovascular events, five-point com- posite‖ 670 (13.9) 3.6 777 (16.1) 4.3 0.84 (0.76–0.93)
- Major adverse limb events · Table 2, confirmatory secondary outcomes
Major adverse limb events, two-point composite¶ 71 (1.5) 0.4 99 (2.1) 0.5 0.71 (0.52–0.96)
- Coronary revascularisation · Table 2, supportive secondary outcomes
Coronary revascularization 200 (4.1) 1.1 263 (5.5) 1.4 0.75 (0.62–0.90)
- Hospitalisation for unstable angina · Table 2, supportive secondary outcomes
Hospitalization for unstable angina pectoris 74 (1.5) 0.4 80 (1.7) 0.4 0.92 (0.67–1.26)
Primary sources
- McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392(20):2001-2012. PMID: 40162642.
- Novo Nordisk A/S. Semaglutide Cardiovascular Outcomes Trial in Patients With Type 2 Diabetes (SOUL). ClinicalTrials.gov identifier NCT03914326. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT03914326
How to cite this page
Medical Adviser's Group. Incretin Atlas: SOUL. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/soul/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.